Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413552 · ClinicalTrials.gov registry record · Phase 1
INDV-2000 First in Human
A Phase 1 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT04413552 is a Phase 1 study that has completed, run by Indivior. The registered enrollment target is 73 participants.
The verdict
NCT04413552, a Phase 1 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.
Interventions
- DRUG Placebo
- DRUG INDV-2000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2021-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04413552
The ClinicalTrials.gov registry entry for NCT04413552 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04413552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04413552 about?
NCT04413552 is a clinical study titled "INDV-2000 First in Human". This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.
What is the current status of trial NCT04413552?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2020-07-06. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT04413552?
The interventions under investigation include: Placebo (DRUG), INDV-2000 (DRUG).
Who is sponsoring clinical trial NCT04413552?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.